Launches Pre-Implantation IVF Screening Kit EmbryoCellect(TM)
Adelaide, July 2, 2014 AEST (ABN Newswire) - Australian IVF-focussed company Reproductive Health Science (
ASX:RHS) ("RHS") is pleased to advise Managing Director and CEO Dr Michelle Fraser has launched its lead product, EmbryoCellect(TM) at an international forum for reproductive medicine and embryology in Munich, Germany.
RHS is one of 134 exhibitors at the 2014 European Society of Human Reproduction and Embryology Conference (ESHRE) which is a key forum for the IVF community attended by more than 8,500 international delegates. ESHRE runs from 29 June until 2 July 2014.
(http://www.eshre2014.eu)
Commenting from Munich, Dr. Fraser said: "There has been real interest in the EmbryoCellectTM product driven by the increasing awareness and use of Pre-Implantation Genetic Screen (PGS) during the IVF process and the clinical data demonstrating its positive effects on IVF success rates.
"We are encouraged by the positive response EmbryoCellect is receiving from both IVF clinics and distributors."
EmbryoCellect(TM) is a kit that has an immediate application to improve the success rate of In-Vitro Fertilisation (IVF). Following 10 years of research and development, RHS has developed this test specifically to assess embryos for chromosomal number prior to implantation as part of an IVF cycle.
Media Coverage
The Company is also pleased to provide a link to a news piece which highlighted RHS' EmbryoCellect(TM) product and its potential to provide a greater chance of IVF success. Click here to view:
http://www.youtube.com/watch?v=eYM6wKjV_HQ
Managing Director and CEO Dr Michelle Fraser also featured on The Today Show where the significant benefits of EmbryoCellectTM were highlighted. Click here to view:
http://www.jumpin.com.au/show/today/videos/3638371869001
To view the release, please visit:
http://media.abnnewswire.net/media/en/docs/77518-ASX-RHS-682779.pdf
About Reproductive Health Science Ltd
Reproductive Health Science (ASX:RHS) is an advanced biotech company that has successfully developed a test to assess embryos for chromosomal abnormalities prior to implantation as part of an of In-Vitro Fertilisation (IVF) cycle. The two component system has an immediate application to improve the success rate of IVF. The Company's lead product EmbryoCellect(TM) is aimed at improving health and research outcomes through the application of its frontier technologies with the initial primary focus of improving IVF success. Launched in 2014, EmbryoCellect(TM) contains reagents for 20 tests at a list price of AUD$3,600 per kit. RHS's assumption for business modelling purposes, based on IVF industry experience, is that there are 4 embryos per IVF cycle.
| ||
|
